← All news

FROM THE NEWS FEED

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

2026-08-12 • Psychedelic Invest

Article summary

NEW YORK, August 12, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics…

Continue to the original publication for the complete article.